周一，H.C. Wainwright重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价维持在$38.00。该公司的乐观态度源于bexotegrast治疗特发性肺纤维化(IPF)的BEACON-IPF临床试验的进展。该试验正按计划进行，预计患者招募将在2025年第一季度结束。 BEACON-IPF试验是一项为期52周的研究，旨在评估bexotegrast ...

Idiopathic pulmonary fibrosis (IPF), the most common phenotype of IIPs, has a prognosis that is influenced by a number of ...

巴塞罗那官方公布了亚马尔和莱万多夫斯基的伤情，他们都将错过国家队的比赛。 巴萨官方宣布，亚马尔右脚踝韧带联合1级损伤，大约缺席2-3周，莱万多夫斯基腰部受伤，预计缺阵10天。

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report), retaining the price ...

“Currently in Australia small businesses and their customers pay a lot more than big businesses in unfair fees for basic debit card payments,” IPF said in a recent Linkedin post. IPF members have ...

“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...

近日，备受全球华人瞩目的2024年福布斯全球华人精英TOP 100榜单正式揭晓，康蒂尼药业董事会主席罗楹凭借其*的领导力和在医药创新领域的杰出贡献成功入选。这份荣誉不仅彰显了罗楹个人的*成就与不懈努力，更凸显了康蒂尼药业在医药行业的*地位和深远影响。

Bristol-Myers Squibb Company ( NYSE: BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Samit Hirawat - EVP, Chief Medical Officer, Global Drug ...

Investors were quick to overlook the negatives. The post ASX 200 consumer stock surges despite loss and dividend cut appeared ...